Cingulate closed at $4.56 on Nov 4, down 3.39%, 60.9% below its 52-week closing high. Volume of 110.8K shares was 0.92× its 20-day average (close to normal).
Split-adjusted performance: -6.7% over one month, -14.4% over six months, +20.0% over one year.
Short interest was 1.0M shares at the Oct 15 settlement, down 1.4% from the prior report (11.5% of float, 11.8 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CINGCingulate | $4.56 | −3.39% | −14.4% | — | — | — | $66.3M | |
| RANIRani Therapeutics Holdings | $0.5728 | +3.06% | −40.3% | — | −432.7% | — | $66.1M | Compare |
| CPIXCumberland Pharmaceuticals | $4.44 | +3.02% | +1.6% | −56.3% | −2569.0% | — | $66.5M | Compare |
| FBIOFortress Biotech | $1.97 | +1.55% | −22.7% | +14.0% | −13.2% | 0.6 | $65.7M | Compare |
| TENXTenax Therapeutics | $1.81 | −1.63% | −84.9% | — | — | — | $67.7M | Compare |
| TELOTelomir Pharmaceuticals | $0.8750 | −3.85% | −34.7% | — | — | — | $64.5M | Compare |
| CRBPCorbus Pharmaceuticals Holdings | $3.57 | −7.75% | −67.3% | — | — | — | $69.0M | Compare |
| MAIAMAIA Biotechnology | $1.14 | +5.56% | −15.6% | — | — | — | $70.4M | Compare |
| QUCYQuantum Cyber N.V | $0.7430 | +2.65% | — | — | — | — | $62.5M | Compare |
No recent articles focused on Cingulate.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
